Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer
Authors: Alan P. Venook
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. June 28, 2023 FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. June 28, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00324 Journal of Clinical Oncology - published online before print June 28, 2023 PMID: 37379690 Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer Alan P. Venook , MD, FASCO1,2xAlan P. VenookSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA https://doi.org/10.1200/JCO.23.00324 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn the companion to this article, Goldberg et al1 demonstrated that the combination of oxaliplatin with infusional fluorouracil (FOLFOX) in patients with advanced colorectal cancer (CRC) was superior to irinotecan with bolus fluorouracil. Meanwhile, Tournigand et al2 demonstrated that the order in which patients received FOLFOX and fluorouracil, leucovorin, and irinotecan did not change outcomes. These findings established infusional fluorouracil as the standard backbone to which the addition of either oxaliplatin or irinotecan constituted the gold standard for the first-line treatment for advanced CRC.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Alan P. VenookConsulting or Advisory Role: Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Exelixis, BridgeBio Pharma, Bayer Health, Gilead Sciences, Exact Sciences, Bristol Myers Squibb Foundation/Janssen, PfizerPatents, Royalties, Other Intellectual Property: Royalties from Now-UptoDate for authoring and maintaining two chaptersNo other potential conflicts of interest were reported. Companion A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study